Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Current Opinion in Oncology|March 15, 2021
Emerging systemic antitarget treatment for differentiated thyroid carcinomaNeus Basté, Mireia Mora, Juan José Grau
Future Oncology (London, England)|June 6, 2020
Immunotherapy combinations for the treatment of patients with solid tumorsMaria Virginia Bluthgen, Neus Basté, Gonzalo Recondo
Brazilian Journal of Otorhinolaryngology|July 30, 2025
Cancer stem cell biomarkers in locally advanced head and neck squamous cell carcinomaMiguel Caballero-Borrego, Juan J Grau, Neus Basté, et al.
Medicina Clinica|January 8, 2026
Recurrent respiratory papillomatosis treated with combined erlotinib and celecoxib: A retrospective studyThais Lizondo López, Belén López García, Neus Basté, et al.
JCO Precision Oncology|February 9, 2022
Comparison of Treatment Recommendations by Molecular Tumor Boards WorldwideDamian T Rieke, Mario Lamping, Marissa Schuh, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|September 26, 2024
SEOM-GETNE-TTCC Clinical guideline thyroid cancer (2023)Teresa Alonso-Gordoa, Paula Jimenez-Fonseca, Javier Martinez-Trufero, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 6, 2021
Doxorubicin plus lurbinectedin in patients with advanced endometrial cancer: results from an expanded phase I studyRebecca Kristeleit, Victor Moreno, Valentina Boni, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|August 11, 2023
Assessment of the change of antiemetic prophylaxis from double to triple combination in patients with high dose carboplatin chemotherapyMarta Albanell-Fernández, Ángela Pérez Sánchez, Inés Monge-Escartín, et al.
Clinical and Translational Science|March 20, 2021
Exploratory window-of-opportunity trial to investigate the tumor pharmacokinetics/pharmacodynamics of the IAP antagonist Debio 1143 in patients with head and neck cancerCarlos Gomez-Roca, Caroline Even, Christophe Le Tourneau, et al.
Pageof 2